Contact
diode laser transscleral cyclophotocoagulation for refractory glaucoma:
comparison of two treatment protocols
Shirley H.L. Chang,† MD; Yi-Cheng
Chen,* MD; Chia-Yun Li,* MD; Shiu-Chen Wu,† MD ABSTRACT
Background:
Diode laser transscleral cyclophotocoagulation
has shown promising results in the treatment of refractory glaucoma.
Treatment with a lower energy level per pulse and lower total energy
is safer but may be less effective. We performed a study to evaluate
the clinical effectiveness and safety of contact transscleral cyclophotocoagulation
using two different protocols in the treatment of Chinese patients with
refractory glaucoma.
Methods:
Review of the records of 129 patients
with refractory glaucoma who underwent contact transscleral cyclophotocoagulation
for the first time performed by two different surgeons. In group 1 (73
eyes) the output was 2.5 W and the exposure time 2 seconds; in group
2 (56 eyes) the corresponding values were 2.0 W and 1.5 seconds. We
recorded the number of antiglaucoma medications used, Snellen visual
acuity, slit-lamp biomicroscopic findings, intraocular pressure (IOP)
and findings on ophthalmoscopy with pupil dilation before and 1 day,
1 week, 1 month, 3 months and 6 months after treatment.
Results:
The mean age of the patients was 56.4
years (standard deviation [SD] 18.3 years) in group 1 and 53.5 (SD 18.0)
years in group 2.The most frequent diagnoses were neovascular glaucoma
secondary to proliferative diabetic retinopathy or central retinal vein
occlusion, and glaucoma associated with penetrating keratoplasty. The
mean number of laser pulse applications per patient was 27 (SD 5.1)
(range 10–36) in group 1 and 55 (SD 6.1) (range 40–60) in
group 2. One month after treatment, the mean reduction in IOP was 20.2
mm Hg (SD 14.2 mm Hg) in group 1 and 13.7 mm Hg (SD 15.8 mm Hg) in group
2, a significant difference (p = 0.035).There was no difference between
the two groups in the mean reduction in IOP at 6 months (19.1 mm Hg
[SD 15.1 mm Hg] vs. 14.2 mm Hg [SD 16.3 mm Hg]). The mean reduction
in the number of antiglaucoma medications was 1.2 (SD 1.1) in group
1 and 0.6 (SD 1.0) in group 2 (p = 0.003). The incidence rates of transient
hyphema in the anterior chamber (23.3% vs. 7.1%) and of transient exudate
in the anterior chamber (8.2% vs. 0.0%) were significantly higher in
group 1 than in group 2 (p < 0.005).
Interpretation:
To achieve greater IOP reduction
with diode laser transscleral cyclophotocoagulation, an increase in
energy per pulse may be more effective than an increase in total applications.
|